TELO
Telomir Pharmaceuticals Inc
$
1.560
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.580
Open
1.550
VWAP
1.53
Vol
876.91K
Mkt Cap
50.36M
Low
1.460
Amount
1.34M
EV/EBITDA(TTM)
--
Total Shares
29.76M
EV
44.78M
EV/OCF(TTM)
--
P/S(TTM)
--
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.
Show More
Valuation Metrics
The current forward P/E ratio for Telomir Pharmaceuticals Inc (TELO.O) is -5.46, compared to its 5-year average forward P/E of -5.99. For a more detailed relative valuation and DCF analysis to assess Telomir Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-5.99
Current PE
-5.46
Overvalued PE
1.79
Undervalued PE
-13.76
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
5406.75
Current PS
0.00
Overvalued PS
41175.23
Undervalued PS
-30361.72
Financials
Annual
Quarterly
FY2025Q2
0.00
Total Revenue
FY2025Q2
YoY :
+243.84%
-5.07M
Operating Profit
FY2025Q2
YoY :
+249.89%
-5.07M
Net Income after Tax
FY2025Q2
YoY :
+240.00%
-0.17
EPS - Diluted
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
TELO News & Events
Events Timeline
2025-09-18 (ET)
2025-09-18
08:27:57
Telomir Pharmaceuticals Reveals In Vitro Findings for Telomir-1
2025-09-09 (ET)
2025-09-09
08:28:08
Telomir Pharmaceuticals Reveals Preclinical Cancer Findings for Telomir-1
2025-08-28 (ET)
2025-08-28
08:17:26
Telomir Pharmaceuticals Reveals In Vitro Findings for Telomir-1
Sign Up For More Events
Sign Up For More Events
News
4.5
08-28BenzingaStock Market Update: Nvidia Weighs on Nasdaq Futures—Attention on Dollar General, Dell, and Best Buy
9.5
08-28BenzingaSnowflake Shares Surge 14%; Check Out 20 Stocks Making Moves in Premarket Trading
9.0
08-28BenzingaReasons Behind the 35% Surge in Telomir Pharmaceuticals Stock on Wednesday Night
Sign Up For More News
People Also Watch
LARK
Landmark Bancorp Inc
26.670
USD
-1.48%
MRAM
Everspin Technologies Inc
8.600
USD
+8.18%
SKYX
SKYX Platforms Corp
1.320
USD
+1.54%
GGR
Gogoro Inc
0.338
USD
+4.00%
UEIC
Universal Electronics Inc
4.510
USD
-1.74%
QUIK
Quicklogic Corp
6.270
USD
+7.92%
CRBU
Caribou Biosciences Inc
1.930
USD
+14.20%
AISP
Airship AI Holdings Inc
5.630
USD
-3.92%
STIM
Neuronetics Inc
2.840
USD
+2.16%
MMLP
Martin Midstream Partners LP
3.040
USD
+1.67%
FAQ
What is Telomir Pharmaceuticals Inc (TELO) stock price today?
The current price of TELO is 1.56 USD — it has increased 1.96 % in the last trading day.
What is Telomir Pharmaceuticals Inc (TELO)'s business?
What is the price predicton of TELO Stock?
What is Telomir Pharmaceuticals Inc (TELO)'s revenue for the last quarter?
What is Telomir Pharmaceuticals Inc (TELO)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Telomir Pharmaceuticals Inc (TELO)'s fundamentals?
How many employees does Telomir Pharmaceuticals Inc (TELO). have?